Friday, March 6, 2015

Sickle cell drug shows promise in UCD trial

From page A8 | July 06, 2014 |

A UC Davis clinical trial has found safe a drug designed to treat a common, painful complication of sickle cell disease.

There are currently no specific treatments for vaso-occlusive crises, during which clumped-together blood cells hinder blood flow. It is responsible for more than 70,000 hospitalizations annually, according to Ted Wun, associate dean for research at the UCD School of Medicine.

The 15-patient trial found no severe side-effects from the drug, dubbed GMI 1070, and that it was maintaining adequate concentrations in the blood.

Published online in the journal Public Library of Science ONE, the study was not aimed at determining the drug’s effectiveness, but Wun said it did show small improvements in blood flow and reduced the markers of cell activation.

Sickle cell disease, which lowers life expectancy by 20 to 30 years, affects an estimated 90,000 to 100,000 Americans, mostly blacks, according to the U.S. Centers for Disease Control and Prevention.

It is caused by abnormal hemoglobin that contorts red blood cells into a sickle shape, making them stiff and sticky. These clumped cells reduce blood flow, leading to severe hip, back and long-bone pain, and, often, chest and abdominal pain.

“White blood cells bind to inflamed blood vessel walls and sickle red cells stick to white cells, but interestingly the initiating event is the white cells,” Wun said in a news release. “If we could interrupt that white cell interaction, we could stop the cycle that leads to vaso-occlusions.”

The new drug is designed to do that by mimicking sugars attached to cell-adhesion proteins, called selectins, reducing the stickiness and increasing blood flow.

Sickle cell most often strikes the kidneys, lungs and spleen, but it can affect any organ. Stroke, infections, hypertension and heart failure are among its severe complications.

Patients in the trial tolerated the drug well, with headaches the most common side-effect. Preliminary results of a second trial also have been positive, and have been submitted for publication, according to researchers. A third phase is planned.

“If the phase III study confirms that GMI 1070 is effective, it would be a huge advance for the sickle cell community,” Wun said.

GlycoMimetics Inc., a Maryland-based biotechnology company based in Gaithersburg, produces the new drug under the trade name Rivipansel. The company paid for the trial.

Also this week, National Institutes of Health scientists announced the results of a study that found bone marrow transplants can reverse sickle cell disease. The transplant worked in 26 of 30 adults, and 15 of them were even able to stop taking drugs that prevent rejection one year later.

The treatment is a modified version of bone marrow transplants that have worked in children. Donors are a brother or sister whose stem cell-rich bone marrow is a good match for the patient.

The treatment involves using chemotherapy and radiation to destroy bone marrow before replacing it with healthy donor marrow cells.

Results from the adult study, involving patients aged 29 on average, were published in the Journal of the American Medical Association.

—The Associated Press contributed to this report.



Cory Golden

Cory Golden

The Enterprise's higher-education and congressional reporter.


‘Topping out': Sign a building beam at the Shrem Museum

By Jeffrey Day | From Page: A1 | Gallery

Life after lawn: Fifty greens for shade

By Katie F. Hetrick | From Page: A1

Got sun? Indoor herbs can thrive on windowsills

By The Associated Press | From Page: A3

How can we know that the products we buy for our homes are safe?

By Special to The Enterprise | From Page: A4

Quick home improvements that raise your resale value

By Special to The Enterprise | From Page: A4

Spring-clean your kitchen in five easy steps

By The Associated Press | From Page: A5

Dryers: Homes’ energy guzzlers just got greener

By The Associated Press | From Page: A6

Need a new best friend?

By Enterprise staff | From Page: B6 | Gallery

UCD improving farming, food production with fewer pesticides

By Kathy Keatley Garvey | From Page: B6 | Gallery

PSAs highlight area nonprofits

By Special to The Enterprise | From Page: B6

Peripheral neuropathy support offered

By Enterprise staff | From Page: B6

Workshop eyes creating peace through creative play

By Enterprise staff | From Page: B6

Museum brick sales to end this month

By Enterprise staff | From Page: B6

Cabrillo Club plans membership dinner

By Enterprise staff | From Page: B6

Pig out at Pig Day Saturday

By Enterprise staff | From Page: A11

Porkers on display at Hattie Weber Museum

By Enterprise staff | From Page: A11

St. John’s shows off cuisine at brunch

By Special to The Enterprise | From Page: A11

Seniors serious about fitness

By Savannah Holmes | From Page: A11 | Gallery



Obama’s world is a dangerous place

By Letters to the Editor | From Page: B4

Tom Meyer cartoon

By Debbie Davis | From Page: B4

Some convicts don’t deserve parole hearings

By Tom Elias | From Page: B4

Here’s how to make college cheaper

By Special to The Enterprise | From Page: B4

Dirty laundry on the company line

By Creators Syndicate | From Page: B9



Marsh provides radio images of a ‘magical’ Aggie hoops season

By Bruce Gallaudet | From Page: B1 | Gallery

Blue Devil volleyballers cruise in home opener

By Thomas Oide | From Page: B1 | Gallery

DHS girls track and field team reloads for 2015

By Dylan Lee | From Page: B1 | Gallery

UCD women fall at UCR

By Enterprise staff | From Page: B1

Aggie men clinch Big West crown

By Bruce Gallaudet | From Page: B1 | Gallery

Sports briefs: Bella Vista slips past DHS softballers

By Enterprise staff | From Page: B12



Rec Report: Looking ahead to spring break

By Special to The Enterprise | From Page: B5

What’s happening

By Anne Ternus-Bellamy | From Page: B5

Wineaux: A local diamond in the rough, revisited

By Susan Leonardi | From Page: A9



Steve Kiser’s work on display at Gallery 1855

By Enterprise staff | From Page: A9 | Gallery

Tables available at Vinyl and Music Fair

By Special to The Enterprise | From Page: A9

‘The Second Best Exotic Marigold Hotel': Second-rate

By Derrick Bang | From Page: A10 | Gallery

‘Snow White and the Seven Dwarfs’ auditions set

By Special to The Enterprise | From Page: A12

Hugh Masekela and Vusi Mahlasela celebrate Mandela’s legacy

By Jeff Hudson | From Page: A12 | Gallery

Learn from experts at ‘Art of Painting’ conference

By Enterprise staff | From Page: A12 | Gallery

Tom Brousseau to visit ‘Live in the Loam’ on KDRT

By Special to The Enterprise | From Page: A12



Honey, we shrank the SUV — and Europe loves it

By The Associated Press | From Page: B3 | Gallery





Comics: Friday, March 6, 2015

By Creator | From Page: B10